share_log

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Benzinga ·  Mar 28 20:49

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment